Open access
Open access
Powered by Google Translator Translator

Critical Care & Emergencies (all articles)

RCT: more data showing Azithromycin is not better than placebo in patients with Covid-19.

18 Jul, 2021 | 23:54h | UTC

Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial – JAMA

Commentary: Common antibiotic no more effective than placebo in preventing COVID-19 symptoms among non-hospitalized – University of California – San Francisco

Related: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (several articles on the subject)

 

Commentary on Twitter

 

Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.

18 Jul, 2021 | 23:53h | UTC

Recommendations for use of topical inhalant budesonide in COVID-19 – HNO

Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

 

Review: Acute kidney injury.

18 Jul, 2021 | 23:18h | UTC

Acute kidney injury – Nature Reviews Disease Primers (free for a limited period)

 

Commentary on Twitter

 

Why was a major study on ivermectin for covid-19 just retracted?

16 Jul, 2021 | 11:11h | UTC

Why Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review

See also: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian AND Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog AND Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd

 

Commentary on Twitter (thread – click for more)

 

Short review: The gut in COVID-19.

16 Jul, 2021 | 10:54h | UTC

The gut in COVID-19 – Intensive Care Medicine

 

Commentary on Twitter

 

AAFP Guideline: Pharmacologic Management of COPD Exacerbations.

16 Jul, 2021 | 10:51h | UTC

Pharmacologic Management of COPD Exacerbations: A Clinical Practice Guideline from the AAFP – American Family Physician

 

Pathophysiology of COVID-19-associated acute kidney injury.

16 Jul, 2021 | 10:52h | UTC

Pathophysiology of COVID-19-associated acute kidney injury – Nature Reviews Nephrology

 

M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies.

16 Jul, 2021 | 10:43h | UTC

Higher versus lower positive end-expiratory pressure in patients without acute respiratory distress syndrome: a meta-analysis of randomized controlled trials – Critical Care

 

Review: Sedation in the Intensive Care Unit.

16 Jul, 2021 | 10:31h | UTC

Sedation in the Intensive Care Unit – Current Anesthesiology Reports

 

RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

15 Jul, 2021 | 09:26h | UTC

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine

 

Tramadol: Where do we go from here? – “Tramadol’s unpredictability, unique potential harms, and lack of advantage over other opioids or NSAIDs are now well recognized”.

15 Jul, 2021 | 09:14h | UTC

[131] Tramadol: Where do we go from here? – Therapeutic Initiative

 

M-A: Utility of intravenous Alteplase prior to endovascular stroke treatment.

15 Jul, 2021 | 09:03h | UTC

Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs – Neurology (link to abstract – $ for full-text)

Commentary: Direct thrombectomy, bridging therapy confer similar functional outcomes in stroke – Healio (free registration required)

 

Commentary on Twitter

 

RCT: Lopinavir-ritonavir and hydroxychloroquine worsened outcomes in critically ill patients with COVID-19.

14 Jul, 2021 | 11:25h | UTC

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial – Intensive Care Medicine

 

Commentary on Twitter (thread – click for more)

 

RCT: Neither Remdesivir nor Hydroxychloroquine affect viral clearance in hospitalized patients with COVID-19.

14 Jul, 2021 | 11:23h | UTC

News release: Neither remdesivir nor HCQ affect viral clearance in hospitalized patients with COVID-19 – American College of Physicians

Original Study: Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 – Annals of Internal Medicine

 

Commentary on Twitter

 

FDA Safety Alert: hydroxyethyl starch products should not be used unless adequate alternative treatment is unavailable.

14 Jul, 2021 | 10:48h | UTC

Labeling Changes on mortality, kidney injury, and excess bleeding with hydroxyethyl starch products – U.S. Food and Drug Administration

Commentary: FDA Piles on New Warnings for Blood Volume Expanders – MedPage Today (free registration required)

Related: Hydroxyethyl-starch Solutions (HES) Should no Longer be Used – European Medicines Agency AND Randomized Trial: Hydroxyethyl Starch vs. Saline for Volume Replacement Therapy in High-Risk Patients Undergoing Major Abdominal Surgery AND Systematic Review: Colloids vs Crystalloids for Fluid Resuscitation in Critically Ill People

 

German national treatment guidance for hospitalized COVID-19 patients.

13 Jul, 2021 | 10:02h | UTC

Key summary of German national treatment guidance for hospitalized COVID-19 patients Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021) – Infection

 

Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.

13 Jul, 2021 | 09:48h | UTC

J&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT

See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times

 

Another RCT evaluating the efficacy and quality of life of antibiotic-only treatment of acute uncomplicated appendicitis.

13 Jul, 2021 | 09:33h | UTC

A Randomized Clinical Trial Evaluating the Efficacy and Quality of Life of Antibiotic-only Treatment of Acute Uncomplicated Appendicitis: Results of the COMMA Trial – Annals of Surgery (link to abstract – $ for full-text)

Related: A Randomized trial comparing antibiotics with appendectomy for appendicitis AND Antibiotics alone for uncomplicated appendicitis: Oral Moxifloxacin almost as good as intravenous Ertapenem + oral Levofloxacin AND Observational study: 67.1% success rate with nonoperative management of children with uncomplicated appendicitis AND Randomized Trial: Quality of Life and Patient Satisfaction at 7-Year Follow-up of Antibiotic Therapy vs. Appendectomy for Uncomplicated Acute Appendicitis AND Meta-Analysis: Antibiotic Treatment vs. Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children AND Nonoperative treatment for nonperforated appendicitis in children: a systematic review and meta-analysis – Pediatric Surgery International

 

Commentary on Twitter

 

Podcast | An Antibiotics Primer.

13 Jul, 2021 | 09:35h | UTC

#284 An Antibiotics Primer, with @IDdocAdi – The Curbsiders

 

M-A: Similar mortality with Fluoroquinolones or Macrolides for the treatment of Legionella Pneumonia.

13 Jul, 2021 | 09:18h | UTC

Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis – Clinical Infectious Diseases (link to abstract – $ for full-text)

 

Review: Infectious disease-associated encephalopathies.

13 Jul, 2021 | 09:30h | UTC

Infectious disease-associated encephalopathies – Critical Care

 

Commentary on Twitter

 

Top 10 pearls for the recognition, evaluation, and management of maternal sepsis.

13 Jul, 2021 | 09:25h | UTC

Top 10 Pearls for the Recognition, Evaluation, and Management of Maternal Sepsis – Obstetrics & Gynecology

 

RCT: Comparison of nebulized ketamine at three different dosing regimens for treating painful conditions in the emergency department.

13 Jul, 2021 | 09:22h | UTC

Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

[Preprint] Heparin for Moderately Ill Patients with Covid-19 – “In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days”.

12 Jul, 2021 | 03:14h | UTC

Heparin for Moderately Ill Patients with Covid-19 – medRxiv

Related: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. AND [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. AND [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19

 

Commentary on Twitter (thread – click for more)

 

RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19.

12 Jul, 2021 | 03:09h | UTC

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial – The Lancet Respiratory Medicine

Commentaries: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases AND Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine

Related: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. AND RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 AND RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 AND [Press release – not published yet] Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial AND Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 AND Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.